[go: up one dir, main page]

MX2019006938A - Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. - Google Patents

Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.

Info

Publication number
MX2019006938A
MX2019006938A MX2019006938A MX2019006938A MX2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A MX 2019006938 A MX2019006938 A MX 2019006938A
Authority
MX
Mexico
Prior art keywords
methods
pulmonary hypertension
compositions
treatment
vasodilator
Prior art date
Application number
MX2019006938A
Other languages
English (en)
Inventor
Donovan Martin
Weers Jeffrey
Smyth Hugh
Curtis Robert
frost Adaani
Shreeniwas Revati
Romero Alain
Xu Zhen
Original Assignee
Respira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respira Therapeutics Inc filed Critical Respira Therapeutics Inc
Publication of MX2019006938A publication Critical patent/MX2019006938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente métodos para tratar hipertensión pulmonar. Los métodos incluyen administrar a un sujeto en necesidad del mismo una cantidad efectiva de un vasodilatador, en donde el vasodilatador se administra al sujeto por la vía de la inhalación pro re nata o como sea requerido utilizando un inhalador portátil. En algunas modalidades, el vasodilatador es un inhibidor PDE5. También se describen composiciones farmacéuticas para administración pro re nata de los vasodilatadores.
MX2019006938A 2016-12-14 2017-12-14 Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. MX2019006938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662434185P 2016-12-14 2016-12-14
PCT/US2017/066519 WO2018112258A1 (en) 2016-12-14 2017-12-14 Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Publications (1)

Publication Number Publication Date
MX2019006938A true MX2019006938A (es) 2019-09-06

Family

ID=60888760

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006938A MX2019006938A (es) 2016-12-14 2017-12-14 Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.

Country Status (10)

Country Link
US (5) US10912778B2 (es)
EP (2) EP3554507A1 (es)
JP (3) JP2020502121A (es)
CN (1) CN110381951A (es)
AU (3) AU2017378409A1 (es)
BR (1) BR112019012251A2 (es)
CA (1) CA3046025A1 (es)
MX (1) MX2019006938A (es)
RU (1) RU2019121646A (es)
WO (1) WO2018112258A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2017192993A1 (en) 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
US20180325908A1 (en) * 2017-01-10 2018-11-15 United Therapeutics Corporation Methods and compositions for treating pulmonary hypertension
CN114144229A (zh) * 2019-04-10 2022-03-04 梅约医学教育与研究基金会 心血管功能障碍的性别依赖性治疗方法和材料
US20220296521A1 (en) * 2019-06-10 2022-09-22 Respira Therapeutics, Inc. Carrier-based formulations and related methods
CN112569210B (zh) * 2019-09-27 2023-09-15 盈科瑞（天津）创新医药研究有限公司 一种吸入用马昔腾坦溶液及其制备方法
CN112773898A (zh) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
CN115485000A (zh) 2020-03-31 2022-12-16 索芙特海尔公司 至少两种液体组合物的气溶胶递送
US11013688B1 (en) * 2020-05-28 2021-05-25 Softhale Nv Methods of treatment of viral diseases
KR20230096998A (ko) * 2020-10-28 2023-06-30 인스메드 인코포레이티드 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
US20250000873A1 (en) 2021-09-10 2025-01-02 Justus-Liebig-Universitaet Giessen Inhaled iloprost for rescue treatment and treatment as needed in pulmonary hypertension
WO2024249775A2 (en) * 2023-05-31 2024-12-05 Respira Therapeutics, Inc. Methods for treatment of pulmonary hypertension
CN116687888A (zh) * 2023-06-02 2023-09-05 苏州易合医药有限公司 伐地那非和达泊西汀复方干粉吸入制剂及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
US4883810A (en) 1976-08-17 1989-11-28 Burroughs Wellcome Co. Ethers
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
DE3417638A1 (de) 1984-05-10 1985-11-14 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur bestimmung geringer stoffmengen von arzneimitteln, von koerpereigenen oder anderen chemischen substanzen in biologischem material
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
IL135462A0 (en) 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
EP1200091B1 (en) 1999-08-03 2008-07-02 Lilly Icos LLC Pharmaceutical composition comprising tadalafil
IL148291A0 (en) 1999-09-16 2002-09-12 Tanabe Seiyaku Co Aromatic nitrogen-containing 6-membered cyclic compounds
ES2381862T3 (es) 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
HRP20030751A2 (en) 2001-03-28 2005-08-31 Pfizer Inc. N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20040077624A1 (en) 2002-05-23 2004-04-22 Pfizer Inc. Novel combination
CA2536293A1 (en) 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating copd and pulmonary hypertension
US20070031349A1 (en) 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors
CA2641393C (en) 2006-02-03 2014-12-16 Scidose Llc Novel epoprostenol formulation and method of making thereof
KR101390579B1 (ko) * 2006-05-15 2014-05-19 유나이티드 세러퓨틱스 코오포레이션 정량 흡입기를 사용한 트레프로스티닐 투여
KR20160048222A (ko) 2007-12-17 2016-05-03 유나이티드 세러퓨틱스 코오포레이션 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법
CA2710349A1 (en) 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
KR20220031743A (ko) 2008-03-18 2022-03-11 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
WO2009115235A1 (en) 2008-03-20 2009-09-24 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of pulmonary hypertension
SI3300729T1 (sl) 2008-08-13 2020-02-28 Actelion Pharmaceuticals Ltd. Terapevtski sestavki, ki vsebujejo macitentan
ES2797124T3 (es) 2009-06-26 2020-12-01 Nippon Shinyaku Co Ltd Cristales
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EP2480526A1 (en) 2009-09-23 2012-08-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
EP3108888B1 (en) * 2010-03-15 2020-02-12 United Therapeutics Corporation Treatment for pulmonary hypertension
AU2011250485B2 (en) 2010-05-03 2016-07-07 Tsh Biopharm Corporation, Limited Pharmaceutical composition and method for treating hypertension
KR101491938B1 (ko) 2010-07-14 2015-02-10 노파르티스 아게 Ｉｐ 수용체 효능제 헤테로시클릭 화합물
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
WO2012078804A1 (en) 2010-12-07 2012-06-14 Respira Therapeutics, Inc. Dry powder inhaler
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
US9486427B2 (en) 2012-10-31 2016-11-08 Vectura Gmbh Administration of aerosolised iloprost
WO2015089105A1 (en) * 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN106794325B (zh) 2014-02-21 2020-06-30 瑞必治公司 粉末吸入器、系统和方法
WO2016114993A1 (en) * 2015-01-13 2016-07-21 Selten Pharma, Inc. Combination therapy for pulmonary hypertension
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Also Published As

Publication number Publication date
EP4620525A3 (en) 2025-12-03
RU2019121646A3 (es) 2021-03-17
RU2019121646A (ru) 2021-01-15
US20220079949A1 (en) 2022-03-17
US12263174B2 (en) 2025-04-01
EP4620525A2 (en) 2025-09-24
US11491160B2 (en) 2022-11-08
CA3046025A1 (en) 2018-06-21
JP2023036678A (ja) 2023-03-14
EP3554507A1 (en) 2019-10-23
US10912778B2 (en) 2021-02-09
US20250195531A1 (en) 2025-06-19
AU2022256085A1 (en) 2022-11-17
JP2025065408A (ja) 2025-04-17
US20210205318A1 (en) 2021-07-08
US11491161B2 (en) 2022-11-08
AU2025260006A1 (en) 2025-11-20
CN110381951A (zh) 2019-10-25
US20220347183A1 (en) 2022-11-03
JP2020502121A (ja) 2020-01-23
WO2018112258A1 (en) 2018-06-21
BR112019012251A2 (pt) 2019-11-05
AU2017378409A1 (en) 2019-07-04
US20200093830A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
MX2019006938A (es) Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
ZA202103404B (en) Composition and method for treating the lungs
EA201691375A1 (ru) (2s)-n-[(1s)-1-циано-2-фенилэтил]-1,4-оксазепан-2-карбоксамиды в качестве ингибиторов дипептидилпептидазы i
ZA202204929B (en) Rimegepant for cgrp related disorders
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
NO20072920L (no) Kombinasjon av metylxantinforbindelser og steroider for a behandle kroniske respirasjonssykdommer
EA201370230A1 (ru) Новые ингибиторы rock
RU2017134443A (ru) Способ лечения с применением традипитанта
MY184654A (en) Novel dosage form and formulation of abediterol
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
EA201791780A1 (ru) Ингаляционный раствор тиотропия для небулайзерного распыления
EA201590019A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
MX2020001254A (es) Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf.
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
MX372705B (es) Composición farmacéutica que contiene budesonida y formoterol
MX2021014343A (es) Una composicion de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona.
UA83932U (ru) Способ лечения больных хроническим обструктивным заболеванием легких, совмещенным с неалкогольным стеатогепатитом